Obstructive sleep apnoea (OSA) has been reported in approximately 10% of women and 20% of men in the age range 30-60 years. OSA leads to daytime sleepiness in approximately 20% of patients with moderate to severe conditions. Sleepiness-related accidents and cardiovascular disease (hypertension, ischaemic heart disease and stroke) are overrepresented. The mechanistic link between OSA and these complications has been attributed to fragmented sleep and nocturnal hypoxia. OSA has also been linked to vascular inflammation and increased autonomic activity as well as to the metabolic syndrome.
OSA can be treated but current therapies are fully tolerated by no more than some 50% of patients. CPAP-treatment includes a flow-generator (pump) and a nasal mask which is applied exclusively during sleep. Other methods include dental devices and, in some selected cases, upper airway surgery. The number of patients seen by sleep specialists in the country has increased steadily during the last 20 years. Sleep centres have been linked to Pulmonology, ENT medicine, neurology/neurophysiology, cardiology and obesity units. The number of patients investigated annually is estimated to 25,000. The annual volume of new CPAP devices in Sweden is approximately 15,000 distributed across 40-50 prescribing units.
Personally fitted dental devices (annual volume approximately 10,000) are prescribed by 100-150 dentists. There are approximately 100,000 patients with treated OSA in the country.
The purpose of the Swedish Sleep Apnoea Registry is to promote basic research, applied research and clinical activities related to sleep and wakefulness.
Note: Variable lists are updated on a regular basis and should therefore be seen as preliminary. For the latest version, please contact the registry.
Category: Other areas
Certification level: 3
Tack för att du hjälper oss!